Implementation of Newer Radiotherapeutic Technology in the Management of Prostate Cancer

  • Mack Roach
  • Barby Pickett
  • Pamela F. Akazawa
  • Michael Weil
Part of the Cancer Treatment and Research book series (CTAR, volume 93)


The implementation of newer radiotherapeutic technologies is by definition an ever moving target. By the time this chapter is published, it is likely that at least some of the problems and issues discussed will cease to be problems, while others will cease to be of interest. To protect the timeliness of this chapter, a major emphasis has been placed on the principles that underlie the clinical challenges for the implementation of this newer technology. Because the literature is vague and lacking in this area, we will focus primarily on newer technology that has been implemented at the University of California San Francisco (UCSF) within the past few years.


Prostate Cancer Dose Distribution Prostate Volume Localize Prostate Cancer Advanced Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roach M, Rosenthal S, Hunter D, et al. 1993. 100 consecutive patients treated for clinically localized prostate cancer by six field conformai radiotherapy: Acute toxicity and lessons learned — the UCSF/Davis experience. Radiology 189: 183.Google Scholar
  2. 2.
    Roach M, Meehan S, Weil M, et al. 1996. Radiotherapy (XRT) for high-grade (HG) clinically localized adenocarcinoma of the prostate (CAP). Proc ASCO 15:238.Google Scholar
  3. 3.
    Roach M, Burton E, Kroll S, et al. 1996. 501 men irradiated for clinically localized prostate cancer (1987–1995): Preliminary analysis of experience at UCSF and affliated facilities. Int J Radiat Oncol Biol Phys 36(Suppl. 1):248.CrossRefGoogle Scholar
  4. 4.
    Hanks GE, Schulthesis TE, Hanlon A, et al. 1996. Dose esacalation in the conformai treatment of prostate cancer: Optimization is made possible by understanding the dose responses for control of cancer and late morbidity. Int J Radiat Oncol Biol Phys 36(Suppl. 1).Google Scholar
  5. 5.
    Hanks GE, Lee WR, Hanlon A, et al. 1996. Conformai technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pre-treatment prostate-specific antigen ≥10ng/ml. Int J Radiat Oncol Biol Phys 35:861–868.PubMedCrossRefGoogle Scholar
  6. 6.
    Blasko JC, Grimm PD, Ragde H. 1993. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 3:240–249.PubMedCrossRefGoogle Scholar
  7. 7.
    Roach M, Pickett B, Holland J, et al. 1993. The role of the urethragram during simulation for localized prostate cancer. Int J Radiat Oncol Biol Phys 25:299–307.PubMedCrossRefGoogle Scholar
  8. 8.
    Chiru P, Vijayakumar S, Myrianthopoulos L, et al. 1992. Four, six, or eight field technique in the conformai radiotherapy in prostate cancer: A dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 24(Suppl. 1):281.Google Scholar
  9. 9.
    Haraf DJ, Kuchnir FT, Watson-Bullock S, et al. 1993. A dosimetric study comparing three-, four-, and six-field plans for treatment of carcinoma of the prostate. Med Dosim 17:191–198.Google Scholar
  10. 10.
    Roach M, Pickett B, Phillips TL. 1993. The advantages and limitation of three-dimensionally (3-D) based coplanar conformai external beam irradiation (XRT) in the treatment of localized prostate cancer. In ••, ed. European Association of Radiology, 1993. Three-Dimensional Treatment Planning, Vol. 5th Workshop on 3-D planning.Google Scholar
  11. 11.
    Neal AJ, Oldham M, Dearnaley DP. 1995. Comparisons of treatment techniques for conformai radiotherapy of the prostate using dose volume-histograms and normal tissue complication probablities. Radiother Oncol 37:29–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Roach M. 1996. Re: Comparisons of treatment techniques for conformai radiotherapy of the prostate using dose volume-histograms and normal tissue complication probablities [letter]. Radiother Oncol 40:85–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Pickett B, Roach M, Horine P, et al. 1994. Optimization of the oblique angles in the treatment of prostate cancer during six-field conformai radiotherapy. Med Dosim 19:237–254.PubMedGoogle Scholar
  14. 14.
    Pickett B, Roach M, Verhey L, et al. 1995. The value of non-uniform margins for six-field con-formal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 32:211–218.PubMedCrossRefGoogle Scholar
  15. 15.
    Roach M, Akazawa PF, Pickett B, et al. 1994. Bilateral arcs using “averaged beam’s eye views”: A simplified technique for delivering 3-D based conformai radiotherapy. Med Dosim 19:159–168.PubMedGoogle Scholar
  16. 16.
    Weil M, Pickett B, Roach M, et al. 1995. A three field technique for treating prostate cancer. Int J Radiat Oncol Biol Phys 32(Suppl. 1):186.CrossRefGoogle Scholar
  17. 17.
    Rosenthal SA, Roach M III, Goldsmith BJ, et al. 1993. Immobilization improves the reproducibility of patient positioning during six-field conformai radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 29:921–926.CrossRefGoogle Scholar
  18. 18.
    Ten Haken RK, Forman JD, Heimburger DK, et al. 1991. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys 20:1317–1324.PubMedCrossRefGoogle Scholar
  19. 19.
    Roeske JC, Forman JD, Mesina CF, et al. 1995. Evaluation of changes in size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys, in press.Google Scholar
  20. 20.
    Roach M, Faillace-Akazawa P, Malfatti C. 1995. Prostate volumes defined by serial CT scans during delivery of 3D conformai radiation therapy in patients receiving and not receiving hormone therapy. Radiology 197(Suppl.):330.Google Scholar
  21. 21.
    Roach M, Pickett B, Rosenthal S, et al. 1994. Defining treatment margins for 3-D based six field conformai (SFC) irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 28:267–275.PubMedCrossRefGoogle Scholar
  22. 22.
    Pickett B, Roach M. 1996. The impact of isocenter placement errors associated with dose distributions used in irradiating prostate cancer. Med Dosim 21:61–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Roach M, Faillace-Akazawa P, Malfatti C, et al. 1996. Prostate volumes defined by magnetic resonace imaging and computerized tomographic scans for three-dimensional conformai radiotherapy. Int J Radiat Oncol Biol Phys 35:1011–1018.PubMedCrossRefGoogle Scholar
  24. 24.
    Kagawa K, Lee WR, Schultheiss TE, et al. 1996. Clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformai radiation therapy. Int J Radiat Oncol Biol Phys 36(Suppl. 1):246.CrossRefGoogle Scholar
  25. 25.
    Roach M, Holland J, Chan A, et al. 1994. Markers, CTs, urethrograms, and the prostatic apex. Int J Radiat Oncol Biol Phys 31:207–208.CrossRefGoogle Scholar
  26. 26.
    Roach M, Chinn DM, Holland J, et al. 1996. A pilot survey of sexual function and quality of life following 3-D conformai radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 35:869–874.PubMedCrossRefGoogle Scholar
  27. 27.
    Broderick G, Malkowicz SB, Ardalen KV, et al. 1995. Erectile dysfunction following therapy for localized prostate cancer: The role of penile blood flow study. J Urol PS. 330A, 405:153.Google Scholar
  28. 28.
    Diaz AZ, Roach M, Marquez C, et al. 1994. Indications for and significance of including the seminal vesicles during 3-D conformai radiotherapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 30:323–329PubMedCrossRefGoogle Scholar
  29. 29-.
    Roach M, Marquez C, Yuo H, et al. 1993. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37.CrossRefGoogle Scholar
  30. 30.
    Hanks GE, Martz KL, Diamond JJ. 1988. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299–1305.PubMedCrossRefGoogle Scholar
  31. 31.
    Leibel SA, Hanks GE, Kramer S. 1984. Patterns of care outcome studies: Results of the National Practice in Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys 10:401–409.PubMedCrossRefGoogle Scholar
  32. 32.
    Crook JM, Perry GA, Robertson S, et al. 1995. Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 45:624–632.PubMedCrossRefGoogle Scholar
  33. 33.
    Scardino PT, Wheeler TM. 1988. Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 7:95–100.PubMedGoogle Scholar
  34. 34.
    Schellhammer PF, El-Mahdi AM, Wright GL, et al. 1993. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 42:13–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Kabalin JN, Hodge KK, McNeal JE, et al. 1989. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142:326.PubMedGoogle Scholar
  36. 36.
    Bermudez M-A, Roach M, Rosenthal S, et al. 1995. The impact of age and conformai technique on acute toxicity in patients receiving therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:253A.CrossRefGoogle Scholar
  37. 37.
    Sandier HM, Perez-Tamayo C, Ten Haken RK, et al. 1992. Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformai therapy. Radiother Oncol 23: 53–54.CrossRefGoogle Scholar
  38. 38.
    Vijayakumar S, Awan A, Karrison T, et al. 1993. Acute toxicity during external-beam radiotherapy for localized prostate cancer: Comparison of different techniques. Int J Radiat Oncol Biol Phys 25:359–371.PubMedCrossRefGoogle Scholar
  39. 39.
    Lyman J, Wolbarst AB. 1987. Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histogram. Int J Radiat Oncol Biol Phys 13: 103–109.PubMedCrossRefGoogle Scholar
  40. 40.
    Kutcher GJ, Burman C, Brewster L, et al. 1991. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 21:137–146.PubMedCrossRefGoogle Scholar
  41. 41.
    Roach M, Pickett B, Weil M, et al. 1996. The “critical volume tolerance method” for estimating the limits of dose escalation during three-dimensional conformai radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 35:1019–1025.PubMedCrossRefGoogle Scholar
  42. 42.
    Roach M, Pickett B, F-Akazawa P, et al. 1997. Predicting the probability of Gl and GU complications using DVHs and the published literature. (Work in Progress).Google Scholar
  43. 43.
    Carol MP, Targovnik H, Smith D, et al. 1992. 3-D planning and delivery system for optimized conformai therapy. Int J Radiat Oncol Biol Phys 24(Suppl. 1):158.Google Scholar
  44. 44.
    Mohan R, Zelefsky M, Yang J, et al. 1996. The potential of optimized intensity modulation to escalate prostate dose to 86.4 Gy. Int J Radiat Oncol Biol Phys 36(Suppl. 1):197.CrossRefGoogle Scholar
  45. 45.
    Ling CC, Burman C, Chui CS, et al. 1996. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf colimation. Int J Radiat Oncol Biol Phys 35: 721–730.PubMedCrossRefGoogle Scholar
  46. 46.
    Cionini L, Bucciolini M. 1993. Role of portal imaging in clinical radiotherapy: Florence experience. Radiother Oncol 29:230–236.PubMedCrossRefGoogle Scholar
  47. 47.
    Baiter JM, Chen GT, Pelizzari CA, et al. 1993. Online repositioning during treatment of the prostate: A study of potential limits and gains. Int J Radiat Oncol Biol Phys 27:137–143.Google Scholar
  48. 48.
    Baiter JM, Lam KL, Sandier HM, et al. 1995. Automated localization of the prostate at the time of treatment using implanted radiopaque markers: Technical feasibility. Int J Radiat Oncol Biol Phys 33:1281–1286.CrossRefGoogle Scholar
  49. 49.
    Hanley J, Mageras GS, Sun J, et al. 1995. The effects of out-of-plane rotations on two dimensional portal image registration in conformai radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 33:1331–1343.PubMedCrossRefGoogle Scholar
  50. 50.
    Gilhuijs KG, van de Ven PJ, van Herk M. 1996. Automatic three-dimensional inspection of patient setup in radiation therapy using portal images, simulator images, and computed tomography data. Med Phys 23:389–399.PubMedCrossRefGoogle Scholar
  51. 51.
    Bel A, Vos PH, Rodrigus PT, et al. 1996. High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging. Int J Radiat Oncol Biol Phys 35:321–332.PubMedCrossRefGoogle Scholar
  52. 52.
    Holupka EJ, Kaplan ID, Burdette EC, et al. 1996. Ultrasound image fusion for external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 35:975–984.PubMedCrossRefGoogle Scholar
  53. 53.
    Shipley WU, Verhey LJ, Munzenrider JE, et al. 1995. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformai protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Benk VA, Adams JA, Shipley WU, et al. 1993. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate cancer. Int J Radiat Oncol Biol Phys 26:551–557.PubMedCrossRefGoogle Scholar
  55. 55.
    Forman JD, Duclos M, Giacalone S, et al. 1995. Preliminary results of toxicity, biochemical and histological respones in patients with carcinoma of the prostate treated on a prospective dose-finding study with 3-D conformai mixed neutron and photon irradiation. Int J Radiat Oncol Biol Phys 32:252.CrossRefGoogle Scholar
  56. 56.
    Krieger JN, Krall JM, Laramore GE, et al. 1989. Fast neutron radiotherapy for locally advanced prostate cancer. Urology 34:1–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Laramore GE, Krall JM, Thomas FJ, et al. 1985. Fast neutron radiotherapy for locally advanced prostate cancer: Results of an RTOG randomized study. Int J Radiat Oncol Biol Phys 11:1621–1627.PubMedCrossRefGoogle Scholar
  58. 58.
    Russell KJ, Caplan RJ, Laramore GE, et al. 1993. Photons versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Results of a randomized prospective trial. Int J Radiat Oncol Biol Phys 28:47–54.CrossRefGoogle Scholar
  59. 59.
    Saroja KR, Cohen L, Hendrickson FR, et al. 1990. Prostate antigen levels in locally advanced prostate cancer patients treated with high energy neutrons at Fermilab. Int J Radiat Oncol Biol Phys 19(Suppl. 1):229.CrossRefGoogle Scholar
  60. 60.
    Haraf DJ, Rubin SJ, Sweeney P, et al. 1995. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33:3–14.PubMedCrossRefGoogle Scholar
  61. 61.
    Blasko JC, Ragde H, Schumacher D. 1987. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endo Hypertherm 3:131–139.Google Scholar
  62. 62.
    Critz FA, Tarlton RS, Holladay DA. 1995. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. 1-125 implant followed by external beam irradiation. Cancer 75:2383–2391.PubMedCrossRefGoogle Scholar
  63. 63.
    Kaye KW, Olson DJ, Lightner DJ. 1992. Improved technique for prostate seed implantation: Combined ultrasound and fluoroscopic guidance. J Endourol 6:61–66.CrossRefGoogle Scholar
  64. 64.
    Wallner KE, Chiu-Tsao S, Roy J, et al. 1991. An improved method for transperineal prostate implants. J Urol 146:90–95.PubMedGoogle Scholar
  65. 65.
    Wallner KE, Roy J, Zelekshy M, et al. 1994. Short-term freedom from disease progression after 1-125 prostate implantation. Int J Radiat Oncol Biol Phys 30:405–409PubMedCrossRefGoogle Scholar
  66. 66.
    Walner K, Roy J, Harrison L. 1996. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14:449–453.Google Scholar
  67. 67.
    Martinez A, Gonzalez J, Stromberg J, et al. 1995. Conformai prostate brachytherapy: Initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 33:1019–1027.PubMedCrossRefGoogle Scholar
  68. 68.
    Stromberg J, Martinez A, Gonzalez J, et al. 1995. Ultrasound-guided high dose rate conformai brachytherapy boost in prostate cancer: Treatment description and preliminary results ofa phase I/II clinical trial. Int J Radiat Oncol Biol Phys 33:161–171.PubMedCrossRefGoogle Scholar
  69. 69.
    D’Amico AV, Coleman CN. 1996. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out. J Clin Oncol 14:304–315.PubMedGoogle Scholar
  70. 70.
    Porter AT, Forman JD. 1993. Prostate brachy-therapy. An overview. Cancer 71:953–958.PubMedCrossRefGoogle Scholar
  71. 71.
    Kurhanewicz J, Vigneron DB, Hricak H, et al. 1996. Three-dimensional H-l MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7 cm3) spatial resolution. Radiology 198:795–805.PubMedGoogle Scholar
  72. 72.
    Labrie F, Cusan L, Diamond P, et al. 1994. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44:29–37.CrossRefGoogle Scholar
  73. 73.
    Soloway MS, Sharifi R, Wajsman Z, et al. 1996. Randomized prospective study — radical prostactomy alone vs. radical prostectomy preceded by androgen blockade in cT2b prostate cancer. J Urol 155(Suppl.):555A.Google Scholar
  74. 74.
    Pilepich MV, Krall JM, Al-Sarraf M, et al. 1995. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616–623.PubMedCrossRefGoogle Scholar
  75. 75.
    Forman J, Porter AT, Kocheril P, et al. 1996. Early termination of prostate cancer hyper-fractionated dose escalation study. Int J Radiat Oncol Biol Phys 36(Suppl. 1):247.CrossRefGoogle Scholar
  76. 76.
    Laverdiere J, Gomez JL, Cusan L, et al. 1997. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247–252.PubMedCrossRefGoogle Scholar
  77. 77.
    Ryu S, Gabel M, Khil MS, et al. 1994. Estramustine: A novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30:99–104.PubMedCrossRefGoogle Scholar
  78. 78.
    Beard C, Buswell L, Rose MA, et al. 1994. Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 29:611–616.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Mack Roach
  • Barby Pickett
  • Pamela F. Akazawa
  • Michael Weil

There are no affiliations available

Personalised recommendations